Amylyx Pharmaceuticals, Inc. Common Stock (AMLX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point
Amylyx Pharmaceuticals (AMLX) is downgraded from 'Strong Buy' to 'Buy' following the discontinuation of AMX0035 for PSP. Company's investment thesis now centers on avexitide, a GLP-1 receptor antagonist in phase 3 LUCIDITY for post-bariatric hypoglycemia, with topline data expected Q3 2026. The company maintains a strong cash position [$317M, funding into 2028], supporting key milestones including potential avexitide commercialization.
Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2025 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. ( AMLX ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Lindsey Allen Justin Klee - Co-Founder, Co-CEO & Director Camille Bedrosian - Chief Medical Officer James Frates - Chief Financial Officer Joshua Cohen - Co-Founder, Co-CEO & Director Conference Call Participants Seamus Fernandez - Guggenheim Securities, LLC, Research Division Joseph Thome - TD Cowen, Research Division Kevin Strang - Goldman Sachs Group, Inc., Research Division Marc Goodman - Leerink Partners LLC, Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division Christopher Chen - Robert W. Baird & Co. Incorporated, Research Division Susan Chor Ananda Ghosh - H.C.
What Makes Amylyx Pharmaceuticals, Inc. (AMLX) a Strong Momentum Stock: Buy Now?
Does Amylyx Pharmaceuticals, Inc. (AMLX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 29.28% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High?
The mean of analysts' price targets for Amylyx Pharmaceuticals (AMLX) points to a 29.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is AMLX Stock a Solid Choice Right Now?
Amylyx has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Camille L. Bedrosian - Chief Medical Officer James M.
Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential
Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential
Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High?
The mean of analysts' price targets for Amylyx Pharmaceuticals (AMLX) points to a 105.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2025 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Lindsey Allen - Vice President Investor Relations and Communications Justin Klee - Co-CEO Camille Bedrosian - Chief Medical Officer Jim Frates - Chief Financial Officer Josh Cohen - Co-CEO Conference Call Participants Michael DiFiore - Evercore ISI Marc Goodman - Leerink Tim Anderson - Bank of America Securities Graig Suvannavejh - Mizuho Joe Beatty – Baird Ananda Ghosh - H.C. Wainwright & Company Dan Akschuti - Pareto Securities Operator Good morning, my name is Liane and I will be your conference operator today.
Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2024 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Josh Cohen - Co-CEO Justin Klee - Co-CEO Camille Bedrosian - Chief Medical Officer Jim Frates - Chief Financial Officer Conference Call Participants Michael DiFiore - Evercore ISI Joe Beatty - Baird Operator Good morning, my name is Jenny and I will be your conference operator today. At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals Fourth Quarter and Full-Year 2024 Earnings Conference Call.
